In vitro and in vivo inhibitory effects of TLR4 agonist, glucopyranosyl lipid A (GLA), on allergic rhinitis caused by Japanese cedar pollen

Allergy ◽  
2019 ◽  
Vol 75 (2) ◽  
pp. 446-449 ◽  
Author(s):  
Koji Matsumoto ◽  
Hideaki Kouzaki ◽  
Sayuri Yamamoto ◽  
Hirotaka Kikuoka ◽  
Ichiro Tojima ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Lipid A ◽  
Japanese Cedar ◽  
Inhibitory Effects ◽  
Tlr4 Agonist ◽  
Japanese Cedar Pollen ◽  
Cedar Pollen

scholarly journals An analysis of factors related to the effect of sublingual immunotherapy on Japanese cedar pollen induced allergic rhinitis

2018 ◽  
Vol 67 (2) ◽  
pp. 201-208 ◽  
Author(s):  
Syuji Yonekura ◽  
Yoshitaka Okamoto ◽  
Daiju Sakurai ◽  
Kimihiro Okubo ◽  
Minoru Gotoh ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Sublingual Immunotherapy ◽  
Japanese Cedar ◽  
Japanese Cedar Pollen ◽  
Cedar Pollen

scholarly journals Absence of Nasal Blockage in a Japanese Cedar Pollen-Induced Allergic Rhinitis Model Mouse

2009 ◽  
Vol 58 (2) ◽  
pp. 171-178 ◽  
Author(s):  
Hiromi Ogita-Nakanishi ◽  
Takeshi Nabe ◽  
Nobuaki Mizutani ◽  
Masanori Fujii ◽  
Shigekatsu Kohno
Keyword(s):  
Allergic Rhinitis ◽  
Japanese Cedar ◽  
Nasal Blockage ◽  
Model Mouse ◽  
Japanese Cedar Pollen ◽  
Cedar Pollen

scholarly journals Investigating Japanese cedar pollen-induced allergic rhinitis and related terms using Google Trends

2020 ◽  
Vol 69 (4) ◽  
pp. 616-618 ◽  
Author(s):  
Tomohisa Iinuma ◽  
Syuji Yonekura ◽  
Daiju Sakurai ◽  
Yosuke Inaba ◽  
Yohei Kawasaki ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Japanese Cedar ◽  
Google Trends ◽  
Japanese Cedar Pollen ◽  
Cedar Pollen

Effects of Probiotics on Allergic Rhinitis Induced by Japanese Cedar Pollen: Randomized Double-Blind, Placebo-Controlled Clinical Trial

2006 ◽  
Vol 143 (1) ◽  
pp. 75-82 ◽  
Author(s):  
Manabu Tamura ◽  
Takashi Shikina ◽  
Tetsuo Morihana ◽  
Masaki Hayama ◽  
Osami Kajimoto ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Allergic Rhinitis ◽  
Japanese Cedar ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Japanese Cedar Pollen ◽  
Cedar Pollen

Re-Treatment with Omalizumab at One Year Interval for Japanese Cedar Pollen-Induced Seasonal Allergic Rhinitis Is Effective and Well Tolerated

2009 ◽  
Vol 149 (3) ◽  
pp. 239-245 ◽  
Author(s):  
Satoshi Ogino ◽  
Toshikazu Nagakura ◽  
Kimihiro Okubo ◽  
Norio Sato ◽  
Masao Takahashi ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Japanese Cedar ◽  
Japanese Cedar Pollen ◽  
One Year ◽  
Cedar Pollen

scholarly journals The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of Pneumonia

Pharmaceutics ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 601
Author(s):  
Robin Michelet ◽  
Moreno Ursino ◽  
Sandrine Boulet ◽  
Sebastian Franck ◽  
Fiordiligie Casilag ◽  
...  
Keyword(s):  
Lipid A ◽  
Bacterial Resistance ◽  
Statistical Modelling ◽  
Modelling And Simulation ◽  
Knowledge Based ◽  
Monophosphoryl Lipid A ◽  
Tlr4 Agonist ◽  
Tract Infections

The treatment of respiratory tract infections is threatened by the emergence of bacterial resistance. Immunomodulatory drugs, which enhance airway innate immune defenses, may improve therapeutic outcome. In this concept paper, we aim to highlight the utility of pharmacometrics and Bayesian inference in the development of immunomodulatory therapeutic agents as an adjunct to antibiotics in the context of pneumonia. For this, two case studies of translational modelling and simulation frameworks are introduced for these types of drugs up to clinical use. First, we evaluate the pharmacokinetic/pharmacodynamic relationship of an experimental combination of amoxicillin and a TLR4 agonist, monophosphoryl lipid A, by developing a pharmacometric model accounting for interaction and potential translation to humans. Capitalizing on this knowledge and associating clinical trial extrapolation and statistical modelling approaches, we then investigate the TLR5 agonist flagellin. The resulting workflow combines expert and prior knowledge on the compound with the in vitro and in vivo data generated during exploratory studies in order to construct high-dimensional models considering the pharmacokinetics and pharmacodynamics of the compound. This workflow can be used to refine preclinical experiments, estimate the best doses for human studies, and create an adaptive knowledge-based design for the next phases of clinical development.

Sign in / Sign up

Export Citation Format

Share Document